The Lyme disease c6 peptide by Elisa is a different type of ELISA test than the one currently used. It was developed at Tulane University and confirms exposure in more than 60% of cases. However, the C6 peptide ELISA test still has many false-negatives, as many ticks carry more than one infection. Therefore, tests for co-infections are also different from Lyme disease.
A recent study has evaluated the use of the C6 peptide test for LB diagnosis in a two-tiered serological scheme. The study population included 200 prospective patients and 255 control subjects. The test panel included the Immunetics Quick ELISA C6 Borrelia assay kit, Virotech Borrelia burgdorferi ELISA, and Liaison Borrelia ELISA. The study found that the C6 test reduced seroprevalence among 200 healthy blood donors.
Twenty Lyme disease samples were used in the panel. Five of the patients were healthy individuals in endemic areas. A detailed list of symptoms at presentation is provided in Table S1. Of these patients, 88% of them were cultured and tested positive for B. burgdorferi. The remaining patients met the criteria for early or late disseminated Lyme disease.
The development of synthetic antigens has provided breakthroughs for antibody-based tests. These antigens are more specific than their WCS counterparts and less cross-reactive. They also give fewer false-positive results. The C6 Peptide ELISA is a good example of such an advancement. If your doctor suspects you have Lyme disease, he should run the test.
The test is highly sensitive, showing 100% sensitivity to rP41 and rOspC-B. The results are promising for diagnostics and disease staging. The research will determine whether these peptides are more sensitive than other antigens. The next step is to determine which of the two antigens are best for Lyme disease. And if rP41 is more specific, a more sensitive test may be needed.
This ELISA test is based on a peptide that replicates the sequence of the invariable region 6 of the VlsE antigen. The C6 peptide ELISA has a high sensitivity, and can also be used to identify patients with Lyme disease after an OspA vaccine. It is recommended for patients who have had a history of LD. When finished, the ELISA plate should be cleaned. ELISA washer is a device to clean the plate.
The C6 peptide ELISA is highly specific and sensitive for detecting B. burgdorferi. Furthermore, this test does not detect anti-OspA antibodies in human samples. Its high sensitivity, specificity, and precision mean that it may be the best test to diagnose Lyme disease. If this test proves to be helpful, it will eliminate the remaining problems associated with serodiagnosis.
The results of this test were consistent with the sensitivity and specificity of the two methods used in this study. It showed promising results in detecting antibodies to B. burgdorferi, which is one of the most common causes of infection in humans. Its sensitivity and specificity were 84% and 92%, respectively, and its sensitivity is high, indicating that it could detect Lyme disease at an early stage.
The MTT approach is a valid alternative to the STT algorithm for the serodiagnosis of Lyme disease. It offers the potential to improve point-of-care testing and give a single-test result for seropositivity. These tests are less expensive and less labor-intensive than the STT algorithm, and provide objective, quantitative results. They can be used in both diagnostic settings and in interpreting results.